Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds

J Pediatric Infect Dis Soc. 2023 Apr 28;12(4):234-238. doi: 10.1093/jpids/piad015.

Abstract

In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable. (NCT04816643).

Keywords: BNT162b2 vaccine; COVID-19; booster; children; immunogenicity; safety.

Publication types

  • Clinical Trial

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine*
  • COVID-19* / prevention & control
  • Humans
  • Immunogenicity, Vaccine
  • SARS-CoV-2
  • mRNA Vaccines

Substances

  • Antibodies, Viral
  • BNT162 Vaccine

Associated data

  • ClinicalTrials.gov/NCT04816643